US Patent Issued to Gracell Biotechnologies (Shanghai) on Feb. 3 for "Engineered immune cells targeting BCMA and their uses thereof" (Chinese Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,191, issued on Feb. 3, was assigned to Gracell Biotechnologies (Shanghai) Co. Ltd. (Shanghai).

"Engineered immune cells targeting BCMA and their uses thereof" was invented by Hua Zhang (Shanghai), Huan Shi (Shanghai), Lianjun Shen (Shanghai), Wei Cao (Shanghai) and Liping Liu (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides an engineered immune cell targeting BCMA and use thereof. In particular, the present invention provides a CAR specifically targeting BCMA, the CAR comprising an antigen-binding domain which is an S-derived scFv, an antibody heavy chain variable region as shown in SEQ ID NO: 9 and an antibody ...